Together, these data suggest that in addition to its requirement for hyperplasia of GLI2A-negative gastric glands in early tumors, mTOR signaling activity at later stages maintains the undifferentiated phenotype of GLI2A-expressing tumor cells, and both of these functions likely contribute to the impaired growth of tumors in rapamycin-treated mice. The gene discussed is MTOR; the disease is neoplasm.